Unveiling Real-World Evidence Strategies in Boston

Real-world evidence UBC

Unveiling Real-World Evidence Strategies in Boston

Real-world evidence in the pharmaceutical industry has increasingly influenced stakeholder decision-making. In the past, such data was collected once a drug had been approved. The industry has since shifted to a proactive approach, collecting data earlier in the clinical trial process – often as early as Phase II.

Such studies require careful design and analysis to produce strong evidence to prove superior product value. Next week, Aaron Berger, PMP, Project Director and Dara Stein, MSc, Senior Research Scientist, will co-present strategies for optimizing study design to meet real-world evidence needs at CBI's Evidence for Value-Based Programs in Boston.

Their session will provide an overview of the current landscape and highlight ways to design and execute observational studies, comparative effectiveness research, and pragmatic trials to generate more meaningful evidence.

If you will be in the area, be sure to check out their presentation for more guidance on collecting the right real-world evidence to demonstrate superior product value. Click here to discover the full range of real-world evidence solutions we offer or contact us to discuss your current needs.

We hope to see you in Boston!